OrganonOGN +0.07%71 Days Payable is 130.41 as of Mar. 2026, which is 1% below its 10-year median of 132.33. GuruFocus rates OGN with a GF Score™ of 71/100 and a GF Value™ of $14.55 (Fairly Valued). The stock has 9 warning signs investors should review. Among 923 Drug Manufacturers companies, Organon ranks better than 68.26% on this metric.
Organon's average Accounts Payable for the
three
months ended in Mar. 2026 was $968 Mil. Organon's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $677 Mil.
Hence, Organon's Days Payable for the
three
months ended in Mar. 2026 was 130.41.
The historical rank and industry rank for Organon's Days Payable or its related term are showing as below:
OGN'
s Days Payable Range Over the Past 10 Years
Min: 41.41 Med: 132.33 Max: 200
Current: 127.57
During the past 8 years, Organon's highest Days Payable was 200.00. The lowest was 41.41. And the median was 132.33.
OGN's Days Payable is ranked better than 68.26% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs OGN: 127.57
Organon's Days Payable
declined
from Mar. 2025 (146.58) to Mar. 2026 (130.41).
It may suggest that Organonaccelerated paying its suppliers.
Organon Days Payable Related Terms
Organon Days Payable Historical Data
* Premium members only.
The historical data trend for Organon's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Organon's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organon Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organon's Days Payable distribution charts can be found below:
* The bar in red indicates where Organon's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Organon's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organon (OGN) has a Days Payable of 130.41 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Organon and its competitors. This is near median its historical median of 132.33. Over the past decade, Organon's Days Payable has ranged from 41.41 to 200.00. According to the industry distribution chart, Organon ranks #293 out of 923 companies in the Drug Manufacturers industry, placing it in the top 31.7%.
Is Organon's Days Payable too high?
Organon's current Days Payable of 130.41 is near median its 10-year median of 132.33. Over the past 10 years, this metric has ranged from a low of 41.41 to a high of 200.00. The Drug Manufacturers industry median Days Payable is 90.98. Organon's value of 130.41 is 43.3% above this industry median. Based on the distribution chart, Organon ranks #293 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Organon has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's Days Payable compare to AMRN and SCLX?
According to the Drug Manufacturers industry distribution chart, Organon ranks #293 out of 923 companies for Days Payable. This puts Organon in the upper half of its industry. The industry median Days Payable is 90.98. Organon's value of 130.41 is 43.3% above this benchmark. Historically, Organon's own Days Payable has ranged from 41.41 to 200.00 over the past decade. While the company's 10-year median is 132.33 vs. the industry median of 90.98, Organon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organon's current Days Payable of 130.41 is 43.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Organon and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organon's current Days Payable is 130.41, which is near median its own 10-year median of 132.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (OGN) is currently considered Fairly Valued. The stock's GF Value™ is $14.55, compared to a current price of $13.48 — trading 7.4% below its estimated fair value. The current Days Payable is 130.41, which is near median its 10-year median of 132.33 and 43.3% above the Drug Manufacturers industry median of 90.98. Organon's overall GF Score™ is 71/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Organon (OGN), the current Days Payable is 130.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organon (OGN) Overvalued in 2026?
Based on GuruFocus' analysis, Organon stock appears to be undervalued.
The current stock price of $13.48 is trading 7.4% below its estimated GF Value™ of $14.55.
GuruFocus considers Organon to be Fairly Valued.
Key valuation signals for OGN:
Days Payable: 130.41 (near median its 10-year median of 132.33)
GF Value™: $14.55 vs. price of $13.48 (7.4% below fair value)
Industry Position: 43.3% above the Drug Manufacturers median (#293 of 923)
No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
71GF Score
Get the complete analysis for OGN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OGN has been successfully added to your 
